ABA Antitrust Podcast: Balanced Approach is Critical to Assessing the Impact of Life Sciences M&A on Innovation

by Hanna | Sep 4, 2024 | Blog Post

On a recent episode of the ABA Antitrust Podcast Our Curious Amalgam, Dr. Penka Kovacheva, Cornerstone Research Vice President and lead author of a paper recently published in Concurrences, “The Impact of Pharmaceutical M&A on Innovation,” discusses many ways in...

ICYMI – BioPharma Dive: Increased Biopharmaceutical M&A Critical to Supporting Early-Stage Breakthroughs

by Hanna | Aug 7, 2024 | Blog Post

A recent article from BioPharma Dive highlights the challenging landscape for biopharmaceutical initial public offerings (IPOs), and the critical role that mergers & acquisitions play in connecting promising innovations with the resources and investment needed to...

Concurrences Law & Economics: M&A Unlocks Economies of Scale and Scope Across the Life Sciences Ecosystem

by Hanna | Jul 31, 2024 | Blog Post

In a recent article published in Concurrences Law & Economics, Cornerstone Research experts Lorenzo Cattivelli, Anca Cojoc, Penka Kovacheva and Maria Salgado highlight ways that mergers and acquisitions (M&A) can contribute to innovation in the...

ICYMI: Ways and Means Field Hearing – Policymakers Must Take a Balanced, Bipartisan Approach to Life Sciences M&A

by Hanna | Jul 24, 2024 | Blog Post

The U.S. House Committee on Ways and Means recently held a field hearing in Salt Lake City, UT: “Access to Health Care in America: Unleashing Medical Innovation and Economic Prosperity.” While discussing the many challenges and unique market dynamics that shape life...

Innovations Advanced by M&A: Breakthrough Treatments for Rare, Aggressive Cancers

by Hanna | Jul 17, 2024 | Blog Post, Innovations Advanced by M&A

This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this...